Skip to main content
Premium Trial:

Request an Annual Quote

Berry Genomics, BioNano Partner on Chromosomal Variation Detection Assays

NEW YORK (GenomeWeb) – Berry Genomics announced today that it has formed a collaboration with BioNano Genomics to develop assays for the detection of chromosomal variations for the Chinese market.

Under the terms of their deal, the companies will co-develop assays that incorporate BioNano's Irys next-generation mapping platform, which is designed to image, map, and analyze DNA at the single-molecule level to reveal structural variation and aid in genome assembly.

Berry will exclusively manufacture and market the assays and a related instrument system in China for clinical use in certain undisclosed indications following clinical validation and regulatory approval. BioNano will continue to market its Irys system in China for research applications.

Additional terms of the arrangement were not disclosed.

"Chromosomal structural variation-based testing is a very rapidly expanding market in China and the existing detection modalities, such as karyotyping, FISH, and microarrays are slow, labor-intensive, and oftentimes deficient in detecting the full spectrum of genetic variation," Berry CEO Daixing Zhou said in a statement. "BioNano is the only company that provides a commercially viable method for the systematic and comprehensive detection of large structural variations."